Abstract
The current therapy for common variable immunodeficiency is based on the administration of intravenous immunoglobulin preparations which may cause severe adverse reactions. Some reports have associated these reactions with IgG anti-IgA antibodies, although this is not yet clear. We analyzed 20 sera from common variable immunodeficiency patients by an enzyme immunoassay to detect IgG anti-IgA and determine its subclass profile. Five patients presented high levels of these antibodies, all of them had IgG1, two had IgG2 and IgG4 and one had IgG3. Three of these five patients were receiving non IgA depleted intravenous immunoglobulin and had no severe adverse reactions. One patient had persisted with similar high levels of IgG anti-IgA during three years. Therefore, the IgG anti-IgA antibodies, regardless to their subclass profile in the common variable immunodeficiency patients sera do not seem to be associated with severe adverse reactions to intravenous immunoglobulins.
Similar content being viewed by others
REFERENCES
Buckley RH: Common variable immunodeficiency. Curr Ther Allergy Immunol Rheumatol, LM Lichtenstein, AS Fauci (eds.), Philadelphia, B.C. Decker Inc.: 301-304, 1988
Chapel HM: Consensus on diagnosis and management of primary antibody deficiencies. Br Med J 308:581-585, 1994
Cunningham-Rundles C: Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. J Clin Immunol 9:22-33, 1989
Sneller MC: New insights into common variable immunodeficiency. Ann Intern Med 118:720-730, 1993
WHO Scientific Group: Primary immunodeficiency diseases. Clin Exp Immunol 109(Suppl 1):1-28, 1997
Yocum MW, Kelso JM: Common variable immunodeficiency: the disorder and treatment. Mayo Clin Proc 66:83-96, 1991
Buckley RH, Schiff RJ: The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325:110-116, 1991
Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boulé A, Cunningham-Rundles S, O'Malley J, Barandun S, Good RA: Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Int Med 101:435-439, 1984
Cunningham-Rundles C, Zhou Z, Mankarius S, Courter S: Longterm use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 13:272-278, 1993
Duhem C, Dicato MA, Ries F: Side-effects of intravenous immune globulins. Clin Exp Immunol 97(Suppl. 1), 1994
Skull S, Kemp A: Treatment of hypogammaglobulinemia with intravenous immunoglobulin, 1973–93. Arch Dis Child 74:527-530, 1996
Cunningham-Rundles C, Wong C, Bjorkander J, Hanson LA: Use of an IgA-depleted intravenous immunoglobulin in a patient with an anti-IgA antibody. Clin Immunol Immunopathol 38:141-149, 1986
Haeney M: Intravenous immune globulin in primary immunodeficiency. Clin Exp Immunol 97(Suppl. 1), 1994
Burks AW, Sampson HA, Buckley R: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia —detection of IgE antibodies to IgA. N Engl J Med 314:560-564, 1986
Leiloka J, Koistinen J, Lehtinen M, Virolainen M: IgA-induced anaphylactic transfusion reactions: a report of four cases. Blood 42:111-119, 1973
Schmidt AP, Taswell HF, Gleich GJ: Anaphylactic transfusion reactions associated with anti-IgA antibody. N Engl J Med 280: 188-193, 1969
Ferreira A, Garcia Rodriguez MC, Martín J, Fontán G: Tienen algún significado clínico los anticuerpos anti-IgA que aparecen en los pacientes con immunodeficiencias tratadas con gammaglobulina intravenosa? Sangre 40:171-173, 1995
Bjorkander J, Hammarstrom L, Smith CIE, Buckley RH, Cunningham-Rundles C, Hanson LA: Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. J Clin Immunol 7:8-15, 1987
Ferreira A, Garcia Rodriguez MC, Lopez-Trascara M, Pascoal Alcedo D, Fontan G: Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gama globulin. Clin Immunol Immunopathol 47:199-207, 1988
Sandler G, Eckrich R, Malamut D, Mallory D: Hemagglutination assays for the diagnosis and prevention of IgA anaphylactic transfusion reactions. Blood 84:2031-2035, 1994
Koskinen S, Hirvonen M, Tolo H: An enzyme immunoassay for the determination of anti-IgA antibodies using polyclonal human IgA. J Immunol Methods 179:51-58, 1995
Vyas GN, Perkins HA, Fudenberg HH: Anaphylactoid transfusion reactions associated with anti-IgA. Lancet 2:312-315, 1968
Jackson S: Normal human sera contain antibodies directed at Fab of IgA. J Immunol 138:2244-2248, 1987
Sundin U, Nava S, Hammarstrom L: Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 112:341-346, 1998
Koistinen J, Heikkila M, Leiloka J: Gammaglobulin treatment and anti-IgA antibodies in IgA-deficient patients. Br Med J 2:923-924, 1978
Vyas GN, Holmdahl L, Perkins HA, Fudemberg HH: Serologic specificity of human anti-IgA and its significance in transfusion. Blood 34:573-581, 1969
Hammarström L, Persson MAA, Smith CIE: Anti-IgA in selective IgA deficiency—In vitro effects and Ig subclass pattern of human anti-IgA. Scand J Immunol 18:509-513, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sato, M.N., da Silva Duarte, A.J. IgG Anti-IgA Subclasses in Common Variable Immunodeficiency and Association with Severe Adverse Reactions to Intravenous Immunoglobulin Therapy. J Clin Immunol 20, 77–82 (2000). https://doi.org/10.1023/A:1006650812886
Issue Date:
DOI: https://doi.org/10.1023/A:1006650812886